share_log

中国抗体-B(03681.HK)拟8月19日举行董事会会议批准中期业绩

China Antibody-B (03681.HK) plans to hold a board of directors meeting on August 19 to approve its mid-term performance.

Gelonghui Finance ·  Aug 6, 2024 17:03

China Antibody-B (03681.HK) announced that the board of directors has scheduled a board meeting on Monday, August 19, 2024 to consider and approve the group's interim performance for the six months ending June 30, 2024, as well as to handle other matters.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment